Top Markets
#1 Black Phoenix Black Phoenix +828.29%
#2 Not in Employment, Education, or Training Not in Employment, Education, or Training +27.18%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.50%
#4 pipedog pipedog +22.01%
#5 Bless Bless +21.83%
#6 SAFEcoin SAFEcoin +20.57%
#7 Magma Finance Magma Finance +20.19%
#8 Beam Beam +19.74%
#9 PondCoin PondCoin +18.75%
#10 YFSX YFSX +15.99%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Palvella Therapeutics, Inc. Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc.

PVLA
Rank in Stocks #6151
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company... Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
Share Price
$153.93
Market Cap
$2.21B
Change (1 day)
-0.26%
Change (1 year)
172.68%
Country
US
Trade Palvella Therapeutics, Inc. (PVLA)

Category

Healthcare
P/B ratio for Palvella Therapeutics, Inc. (PVLA)
P/B ratio as of 2026 TTM: 0
According to Palvella Therapeutics, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Palvella Therapeutics, Inc. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH